Updated results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with EC-naïve metastatic BRAF V600E colorectal cancer (CRC) in the phase 1b/2 HERKULES-3 study.

Authors
Category Primary study
JournalJ. Clin. Oncol.
Year 2024
This article has no abstract
Epistemonikos ID: 6742defe7a5a15bcc3343c9c227ce6e0e8a3f0c7
First added on: Jan 10, 2026